Lenvatinib radiofrequency ablation sequential therapy offers survival benefits for patients with unresectable hepatocellular carcinoma at intermediate stage and the liver reserve of Child–Pugh A category: A multicenter study.
Saved in:
| Title: | Lenvatinib radiofrequency ablation sequential therapy offers survival benefits for patients with unresectable hepatocellular carcinoma at intermediate stage and the liver reserve of Child–Pugh A category: A multicenter study. |
|---|---|
| Authors: | Zhang, Ying1,2,3 (AUTHOR), Numata, Kazushi1 (AUTHOR) kz_numa@yokohama-cu.ac.jp, Imajo, Kento4,5 (AUTHOR), Uojima, Haruki6 (AUTHOR), Funaoka, Akihiro1 (AUTHOR), Komiyama, Satoshi1 (AUTHOR), Ogushi, Katsuaki1 (AUTHOR), Chuma, Makoto1 (AUTHOR), Irie, Kuniyasu2 (AUTHOR), Kokubu, Shigehiro4 (AUTHOR), Yoneda, Masato7 (AUTHOR), Kobayashi, Takashi7 (AUTHOR), Hidaka, Hisashi6 (AUTHOR), Fukushima, Taito8 (AUTHOR), Kobayashi, Satoshi8 (AUTHOR), Morimoto, Manabu8 (AUTHOR), Kagawa, Tatehiro9 (AUTHOR), Hattori, Nobuhiro10 (AUTHOR), Watanabe, Tsunamasa10 (AUTHOR), Iwase, Shigeru11 (AUTHOR) |
| Source: | Hepatology Research. Dec2024, Vol. 54 Issue 12, p1174-1192. 19p. |
| Database: | Academic Search Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
Be the first to leave a comment!
